Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives

Key Points

• The aim is to explore the current clinical progress of PARP inhibitors for ovarian cancer and understand resistance mechanisms.
• Review of global incidence and mortality rates of ovarian cancer.
• Analysis of clinical studies on PARP inhibitors in ovarian cancer treatment.
• Discussion of resistance mechanisms and potential future research directions.
• Ovarian cancer incidence and mortality continue to rise, particularly in China.
• Clinical use of PARP inhibitors shows promise but faces challenges due to resistance mechanisms.
• Future perspectives suggest a need for personalized treatment strategies in ovarian cancer management.